Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...

GLP1R expression in prostate cancer patients and effects of GLP1R agonism on prostate cancer cells. Choice of androgen receptor pathway inhibitors (ARPi) by disease volume and timing of metastases in ...

Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23 ...

Radium-223 re-treatment in mCRPC patients shows a low incidence of hematologic and non-hematologic adverse events, including skeletal-related events. The study reported a median overall survival of 16 ...

1 In radiopharmaceuticals, investigator-initiated research will be presented on XOFIGO ® (radium-223 dichloride) without ADT in patients with BCR and positron emission tomography (PET) findings in the ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at JPMorgan Chase ...